Business Wire

Parvus Therapeutics Enters into Worldwide Collaboration and License Agreement with Genentech to Develop Navacim™ Therapeutics for the Treatment of Autoimmune Diseases

BURLINGAME, Calif. & CALGARY, Alberta--(BUSINESS WIRE)--Parvus Therapeutics, a biopharmaceutical company focused on the development of disease-specific immunoregulatory medicines to treat autoimmune ...
Business Wire

Parvus Therapeutics Announces Exclusive Worldwide License and Collaboration Agreement for the Development and Commercialization of Its Lead Nanomedicine to Treat Type 1 Diabetes

CALGARY, Alberta--(BUSINESS WIRE)--Parvus Therapeutics, a biopharmaceutical company developing disease-modifying nanomedicines to halt or reverse autoimmune disease without causing general immune ...
GEN

Genentech, Parvus Therapeutics Launch Up-to-$800M Autoimmune Collaboration

Genentech, a member of the Roche Group, today launched an up-to-$800 million partnership with Parvus Therapeutics to develop, manufacture, and commercialize new treatments for inflammatory bowel ...
FierceBiotech

Novartis signs collaboration deal with tiny Parvus for diabetes nanomedicine

Novartis, which has had a busy week for its CAR-T and NASH programs, today moved onto diabetes after penning a new pact with virtual Canadian biotech Parvus Therapeutics to use its leading tech. Exact ...
FierceBiotech

Genentech joins immune tolerance field with Parvus hookup

Genentech has teamed up with Parvus Therapeutics to develop immune tolerance drugs. The Roche subsidiary put together an $800 million-plus deal to work with Parvus on drugs to treat autoimmune ...
pharmaphorum

Genentech signs deal with Parvus to tackle inflammatory diseases

Canada’s Parvus Therapeutics has signed a deal with Roche’s Genentech unit to develop, manufacture and market drugs for inflammatory bowel disease, autoimmune liver diseases, and coeliac disease. The ...